Cognitive impairment in people with COVID-19 with mild-moderate symptoms in Ecuador




Alejandro Checa, Mental Health Unite, Hospital de Especialidades Eugenio Espejo, Quito, Ecuador Eliana Navas, Mental Health Unite, Hospital de Especialidades Eugenio Espejo, Quito, Ecuador Verónica Valencia, Mental Health Unite, Hospital de Especialidades Eugenio Espejo, Quito, Ecuador Jessica Alcívar, Mental Health Unite, Hospital de Especialidades Eugenio Espejo, Quito, Ecuador


Background: Complications of COVID-19 can include neurological, psychiatric, psychological, and psychosocial sequelae. Little is known about the consequences of COVID-19 on the cognitive functions of patients in the subacute phase of the disease. Objective: The objective of the study was to determine if there is an incidence of cognitive impairment in patients with COVID-19 with mild to moderate symptoms in the remission phase. Method: This is a cross-sectional study conducted between April 2021 and August 2021 at the Eugenio Espejo Hospital in Quito, Ecuador. The Montreal Cognitive Assessment test was applied to COVID-19 patients with mild to moderate symptoms. Results: A total of 50 subjects were recruited, 88% (n = 44) presented cognitive deterioration and only 12% (n = 6) showed a normal score. Conclusions: In our cohort study, patients with COVID-19 with mild-moderate symptoms are at high risk of cognitive impairment.



Keywords: COVID-19. Cognitive impairment. Mild to moderate.